Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 May 21:15:1382013.
doi: 10.3389/fpsyt.2024.1382013. eCollection 2024.

A 12-month longitudinal naturalistic follow-up of cariprazine in schizophrenia

Claudia Carmassi  1 , Valerio Dell'Oste  1   2   3 , Sara Fantasia  1 , Andrea Bordacchini  1 , Carlo Antonio Bertelloni  1   4 , Pietro Scarpellini  4 , Virginia Pedrinelli  1   2   4
Affiliations

A 12-month longitudinal naturalistic follow-up of cariprazine in schizophrenia

Claudia Carmassi et al. Front Psychiatry. .

Abstract

Background: Cariprazine, a third-generation antipsychotic (TGAs), has demonstrated efficacy in the treatment of schizophrenia with good tolerability profile. Actual real-world literature data are lacking, particularly when exploring its efficacy in the long term. The present study examined the effects of cariprazine treatment on specific psychopathological domains with a particular focus on outcomes and side effects in real-life experience, after a long-term treatment.

Methods: The present 12-month longitudinal naturalistic study included a sample of subjects with a DSM-5-TR diagnosis of schizophrenia, recruited in the outpatients' psychiatric services of university and community hospitals in Italy, naturally treated with cariprazine. The assessments included: a sociodemographic data sheet, the Structured Clinical Interview for the DSM-5 (SCID-5), the Positive and Negative Symptom Scale (PANSS) and the St. Hans Rating Scale (SHRS). The PANSS was also administered after 6 (T1) and 12 (T2) months of treatment with cariprazine while the SHRS at T1.

Results: The total sample consisted of 31 patients, 15 males and 16 females. A significant decrease of the PANSS' subscales, Marder factors and total mean scores emerged at both T1 and T2 with respect to T0. Extrapyramidal symptoms occurred in a minority of patients and in mild or mild/moderate forms: no patient showed moderate forms of psychic/motor akathisia or dystonia, three subjects showed moderate parkinsonism.

Conclusions: This study confirms a good efficacy profile of cariprazine in both positive and negative symptoms in patients with Schizophrenia, combined with a good tolerability profile in extrapyramidal symptoms.

Keywords: cariprazine; extrapyramidal symptoms; psychosis; schizophrenia; side effects.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. The author(s) declared that they were an editorial board member of Frontiers, at the time of submission. This had no impact on the peer review process and the final decision.

Figures

Figure 1
Figure 1
Comparison of PANSS scale single items between T0 (baseline) and T1 (6-months follow-up) in the total sample (N=31) and between T0 and T2 (12-month follow-up) in the total sample (N=29). *p<.05.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Maj M, van Os J, De Hert M, Gaebel W, Galderisi S, Green MF, et al. . The clinical characterization of the patient with primary psychosis aimed at personalization of management. World Psychiatry. (2021) 20:4–33. doi: 10.1002/wps.20809 - DOI - PMC - PubMed
    1. American Psychiatric Association . Diagnostic and Statistical Manual of Mental Disorders, Text Revision Dsm-5-tr, 5th ed. text-revision. Washington, DC, USA: American Psychiatric Press; (2022).
    1. World Health Organization . The Global Burden of Disease: 2004 Update. Geneva: WHO Press; (2008).
    1. Murray CJL, Lopez AD. The Global Burden of Disease. Cambridge, MA: Harvard University Press; (1996). p.21.
    1. Fusar-Poli P, Papanastasiou E, Stahl D, Rocchetti M, Carpenter W, Shergill S, et al. . Treatments of negative symptoms in schizophrenia: meta-analysis of 168 randomized placebo-controlled trials. Schizophr Bull. (2015) 41:892–9. doi: 10.1093/schbul/sbu170 - DOI - PMC - PubMed

LinkOut - more resources